BioAlliance Pharma: Breakthrough Positive Phase III Results With Acyclovir Lauriad(R) Primary And Secondary Endpoints Met – Final Results
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces final positive results of its pivotal phase III clinical study in immunocompetent patients with recurrent herpes labialis (LIP Study) treated with acyclovir Lauriad®. Primary and secondary endpoints have been met with marked efficacy and good tolerance…
Also tagged Acyclovir, Aids, Aids Patients, Breakthrough, Cancer Patients, Efficacy, Endpoints, Herpes, Herpes Labialis, Met, Paris, Pharma, Phase Iii, Recurrent Herpes, Supportive Care, Tolerance
